- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-416/22: Judgment of the General Court of 15 May 2024 – Fresenius Kabi Austria and Others v Commission (Medicinal products for human use – Suspension of national marketing authorisations for medicinal products for human use containing the active substance hydroxyethyl starch (HES), solutions for infusion – Action for annulment – Direct concern – Partial inadmissibility – Obligation to state reasons – Error of law – Manifest error of assessment – Precautionary principle – Proportionality – Article 116 of Directive 2001/83/EC)
ECLI:EU:UNKNOWN:62022TA0416
62022TA0416
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C series
—
C/2024/4085
(Case T-416/22)
(Medicinal products for human use - Suspension of national marketing authorisations for medicinal products for human use containing the active substance hydroxyethyl starch (HES), solutions for infusion - Action for annulment - Direct concern - Partial inadmissibility - Obligation to state reasons - Error of law - Manifest error of assessment - Precautionary principle - Proportionality - Article 116 of Directive 2001/83/EC)
(C/2024/4085)
Language of the case: English
Parties
Applicants: Fresenius Kabi Austria GmbH (Graz, Austria) and the 14 other applicants whose names appear in the annex to the judgment (represented by: W. Rehmann and A. Knierim, lawyers)
Defendant: European Commission (represented by: M. Escobar Gómez and A. Sipos, acting as Agents)
Interveners in support of the defendant: Ireland (represented by: A. Joyce, M. Tierney, M. Browne and D. O’Reilly, acting as Agents, and by P. McCann, Senior Counsel, and E. O’Callaghan, Barrister-at-Law), European Medicines Agency (represented by: S. Marino, S. Drosos and M. van Egmond, acting as Agents)
Re:
By their action based on Article 263 TFEU, the applicants essentially seek annulment of Commission Implementing Decision C(2022) 3591 final of 24 May 2022 concerning, in the framework of Article 107p of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations of medicinal products for human use which contain the active substance ‘hydroxyethyl starch (HES), solutions for infusion’ following an assessment of a post authorisation safety study (‘the contested decision’), in that it requires the Member States concerned to suspend the national marketing authorisations (‘MAs’) for the medicinal products referred to in Annex I thereto.
Operative part of the judgment
The Court:
1.Dismisses the action;
2.Orders Fresenius Kabi Austria GmbH and the other applicants listed in the annex to bear their own costs and pay those incurred by the European Commission, including those relating to the interlocutory proceedings;
3.Orders Ireland and the European Medicines Agency (EMA) to bear their own costs.
*
Language of the case: English.
ELI: http://data.europa.eu/eli/C/2024/4085/oj
ISSN 1977-091X (electronic edition)
—